The patients were excluded if they were eligible for BMT, had received prior IST with ATG or CsA, had received hematopoietic growth factor more than 4 weeks before enrollment in our study, showed evidence of Fanconi anemia, dyskeratosis congenita, or congential bone marrow failure syndrome, showed evidence of myelodysplastic syndrome, or had uncontrolled infection.